Evaluation of *E. coli* Nissle1917 derived metabolites in modulating key mediator genes of the TLR signaling pathway

Sheyda Damoogh†, Mehrad Vosough†, Shima Hadifar3, Masoumeh Rasoli1, Ali Gorjipour4, Sarvenaz Falsafi†* and Ava Behrouzi1,3*  

Abstract  
Objective: Gut-microbiota plays key roles in many aspects like the health and illness of humans. It’s well proved that modification of gut microbiota by probiotics is useful for improving inflammatory bowel disease (IBD) conditions. According to recent studies, different types of bacterial metabolites can affect immune cells and inflammation conditions. The present study aimed to evaluate the anti-inflammatory effects of metabolites of *E. coli* Nissle1917.  
Results: The cell-free supernatant could modulate TNF-α production and affected many crucial mediators in the Toll-like receptor (TLR) signaling pathway. Also, supernatant showed significant dose-dependent properties in this regard. In this study, the TLR signaling pathway was found among probable mechanisms by which probiotics can affect inflammatory situations. These findings provide additional evidence on the use of probiotic metabolites for inhibiting and down-regulating numerous key mediator factors in the TLR signaling pathway. Aberrant or dysfunctional TLR signaling contributes to the development of acute and chronic intestinal inflammatory pathways in IBD. Therefore, finding a component that can affect this process might be considered for therapeutic targets in IBD patients.  
Keywords: EcN, Inflammatory bowel diseases, Probiotics, TLR signaling

Introduction  
Inflammatory bowel disease (IBD) is an umbrella term for a group of intestinal disorders that cause prolonged inflammation of the digestive tract. In general, the gut bacterial population has a crucial effect on either the development or recurrence of the IBD [1]. Today, IBD treatment is based on using anti-inflammatory drugs, immune modulators substances, and surgery, which may bring a heavy burden on the therapeutic systems [2]. Some researchers reported that animal models without intestinal bacteria flora did not reveal the expansion of inflammatory diseases such as IBD [3]. However, several studies showed that modifying gut microbiota with probiotics can help improve the IBD condition. Also, prescribing a high concentration of probiotics can end in extensive severity of the inflammatory condition in the intestine of IBD patients [4, 5]. Toll-like receptors (TLRs), as a member of the pattern recognition receptors (PRRs) families, play an indispensable role in inducing anti-inflammatory or inflammatory response and subsequent activation of adaptive immune responses [6]. TLRs are divided into cell membrane TLRs, which are expressed on the surface of cells (including heterodimers of TLR2 with TLR1 and TLR6 and TLR4–5–6) [7] and intracellular TLRs, which are localized to the endosome, lysosomes, or to endoplasmic reticulum (ER) [8]. TLR signaling pathways include MyD88-dependent pathway.
that used all TLRs (except for TLR3) and can lead to the release of many different inflammatory cytokines [9]. The TRIF-dependent pathway used through TLR3 and 4 can lead to induction of interferon type-1 [10]. TLR signaling pathway has a key role in the innate immune system such that alteration of TLR expression can contribute to IBD. Therefore, aberrant or dysfunctional TLR signaling may contribute to the development of acute and chronic intestinal inflammatory pathways in IBD and impair intestinal homeostasis [11].

*Escherichia coli* Nissle 1917 (EcN; O6:K5:H1), as a probiotic, is attributed to a non-pathogenic and commensal *E. coli*. EcN is used to treat several inflammatory diseases like ulcerative colitis (UC) and Crohn’s disease (CD). The wide use of this strain is because probiotic treatment can promote an anti-inflammatory response. EcN has a positive effect on intestinal homeostasis and microbial balance. In addition, several studies confirmed the therapeutic benefits of this strain [12].

The presence of the metabolites and boosting their population are recommended as effective controlling strategies in IBD studies. Accordingly, in this study, we evaluated the effect of *E. coli Nissle1917* metabolites on TLR signaling gene expression in inflammatory model cell culture. Overall, proposing some microorganisms that are useful for either treatment or identification of different diseases plays a key role in developing next-generation medicine.

**Main text**

**Materials and methods**

*E. coli Nissle1917 culture and preparation of cell-free supernatant*

*Escherichia coli* Nissle 191 strain was grown in Luria-Bertani (LB) broth overnight at 37 °C with shaking (150 rpm). The cell-free supernatant was prepared according to the method proposed by Ogunbanwo [13]. *E. coli* Nissle1917 was grown in LB broth for 24 h at 37 °C. Then, cell-free supernatant was prepared by centrifuging the culture at 20,000 rcf at 4 °C for 20 min. Finally, for removing bacterial bodies, they were filtered through 0.2 μm filters [14].

**Cell culture and create an IBD model cell**

The HT-29 was cultured in high glucose Dulbecco’s modified eagle’s medium (HDMEM), which was supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin and non-essential amino acids in six-well plates at 37 °C in 5% CO2. To mimic inflammatory conditions like IBD circumstance, the culture was treated with pro-inflammatory cytokines. The culture was maintained for 4 weeks to assess monolayer conditions (much more similar to intestinal conditions). In week 3, it was treated with pro-inflammatory cytokines: 10 ng/ml recombinant human IL-1β or 10 ng/ml recombinant human TNFα [15]. After 4 weeks, when HT-29 monolayer was created and the existence of inflammation condition (same as the IBD conditions) was confirmed, the cell line was treated with the minimum inhibitory concentration of *E. coli* Nissle 1917 supernatant and an equal volume of PBS was used as a control well.

**MTT assay**

To evaluate the effect of *E. coli Nissle1917* metabolites on the viability of HT-29 cells, an MTT assay was performed. HT-29 was treated with a minimum inhibitory concentration of *E. coli Nissle1917* metabolites and incubated for 24, 48, and 72 h. Next, the MTT solution (5 mg/ml) was added to each well and incubated at 37 for 3 h. After 3 h, the supernatants were removed and blue crystals were solubilized with dimethylsulfoxide (DMSO). Finally, absorbance was measured at a wavelength of 570 nm [16, 17].

**RNA extraction, cDNA synthesis, and real-time PCR**

Total RNA was extracted from treated cells and control cells. After 48 h and confirming their quality by TRIzol reagent, cDNA was synthesize by SCRIPT cDNA Synthesis Kit (Jena Bioscience) according to the manufacturer's instructions (https://www.jenabioscience.com/). Real-time PCR was performed based on the SYBRGreen method. A sequence of primers is shown in Table 1.

**Analysis of data**

The ΔΔct method was carried out for evaluating and analysis of relative gene expression. We also used different housekeeping genes (B-actin, GAPDH) for choosing a better reference gene. GraphPad Prism 8.0 was used for calculating changes in gene expression and analysis of cytokine as well. A P-value of less than 0.05 was considered statistically significant.

**Results**

**MTT assay**

The efficiency of different concentrations of bacterial cell-free supernatants on the viability of cells was evaluated after 48 h by the MTT assay. Three concentrations of 2.5, 5, and 10 mg/ml were used for this purpose. The concentration level of 10 mg/ml indicated a significant inhibitory effect on HT-29 cell line viability compared to the control sample (p < 0.05). Meanwhile, other concentrations (i.e. 2.5 and 5 mg/ml) did not show a significant inhibitory effect, which indicates that the supernatant of the *E. coli Nissle 1917*, as a probiotic strain, can affect the growth rate of cancerous cell lines. In addition, the efficiency of the cell-free supernatant
was dose-dependent, which allows considering it in future studies on cancer aspects, especially gastrointestinal cancer. Studies that used some probiotic bacteria confirmed that they could reduce inflammation in cancer patients [18]. However, the 5 mg/ml concentration was chosen for continuing the project, because it was intended to evaluate the cell-free supernatant efficiency in total viable cells. Besides, a larger dataset supports this idea that we can modify gene expression without changing its phenotype (Fig. 1).

**Table 1** Sequence of primers used in qPCR in cell line

| Genes Name | Forward Sequence (5'-3') | Reverse Sequence (5'-3') | Refs. |
|------------|--------------------------|--------------------------|-------|
| TLR-1      | GCCCAAGGAAAAAGCACAAAC    | AAGCAGCAATATCAACAGGAG    | [43]  |
| TLR-2      | TCTCCATTTCGCTCTTTT      | GTGCTGGGTCATATCTCT       | [43]  |
| TLR-3      | TAGACTGACCCATGCCTCT      | TATGACGAAAAGGCACCTATC    | [18]  |
| TLR-4      | GAAGCTGCTGCTGCTGGGA     | GATGAGAACCCCGCAAG        | [18]  |
| TLR-5      | TGCTCAACACCTGACACAC     | GCTCTCACAAGACAAAAAGCAT   | [18]  |
| TLR-6      | GTGCTATTACGAACCTAC      | TTGGTGGAACTCCTG          | [18]  |
| TLR-7      | CTGACACATGTCCTCCGAG     | AACCACAGACAAAAACCA       | [18]  |
| TLR-8      | AACATCAAGAACACCCAT      | GACTCTTCATCTCCCT         | [18]  |
| TLR-9      | CGCCAAACCCCCCTCAAGACA   | GGGCTTTACATCTGATTTGC     | [18]  |
| Myd88      | TGGGCCTTGGAGCCCGTGA     | AAGATATTCGGCAATCTCCCT    | [44]  |
| IRAK1      | AGTTTCGGTACCCAAACATT    | CCGCTGTAACCCAGAAG        | [45]  |
| IRAK4      | CTTGACTTCTCAAGTCGCAAG   | ACAAGAATGCGTGCTACTACAA   | [46]  |
| MAPK       | GAGAGGGCTTTATGATCTG     | TTTTCATCCTGTTGACCGA      | [47]  |
| NFkB       | GTCAAAAGGCCACCTAACCA    | CTCGCCATGAAATTTGGAGCC    | [48]  |
| TAB2       | CTTCCGCTGGTACACCTCGC    | TGATTGCGCTTGAGATGAG      | [48]  |
| IFN-β      | CAACCTGGTCTGATTCTCACA   | TATTCGACGCTACCCATTATAG   | [48]  |
| B-actin    | AAGCTGAAAGATGACCACAGAT  | CACAGCCCTGGATGCTACTG     | [19]  |
| GAPDH      | AACGGGGAGCTTTGCAATGAAAA | GCATCAAGCAGAAGGGGCAGAG   | [18]  |

**Effects of E. coli Nissle1917 metabolites on TLRs gene expression levels**

There is a direct correlation between IBD and microbiota. In this regard, we evaluated the expression levels of TLRs genes involved in IBD [11]. The expression levels of TLR-2 showed a statistically significant decrease (p < 0.05) compared to the control sample, while the expression levels of TLR-1, TLR-3, and TLR-7 were increased. The other TLR genes (i.e. TLR-4, TLR-5, TLR-6, and TLR-8) did not show any change in their expression levels over the control sample. According to the findings, most changes were related to a 15-times reduction in TLR-2 expression. Other changes in expression levels ranged from 2 to 5 times compared to the control sample (Fig. 2a).

**Effects of E. coli Nissle1917 metabolites on Myd88, IRAK1, IRAK4, TAB2, MAP3K, and NFkB gene expression levels**

TLRs receptors are located in several cell types such as epithelial cells, macrophages, dendritic cells, T cells, B cells, and endothelial cells [19]. Previous studies that used animal models with a deficiency in Myd88 have confirmed the important role of TLR/MyD88 signaling in the inhibition of intestinal inflammation [20]. Interestingly, all key mediator genes in the TLR signaling pathway that were evaluated in our study, including Myd88, IRAK1, IRAK4, TAB2, MAP3K, and NFkB, showed a significant reduction in the expression level compared to the control sample. However, in contrast, the expression
levels of INF-β1 were increased significantly (Fig. 2b and c and Additional file 1: Figure S1).

Discussion

These days, probiotics are widely using in various pathways for addressing many medical problems [21]. For instance, the emergence of several infectious agents, which are multi-drug-resistant (MDR), has led to public health concerns. Various agents are responsible in this regard, for instance using indiscriminate and inadequate antibiotics [22] or overexpressed efflux pumps, especially in gram-negative bacteria [23]. Therefore, the utilization of probiotics, instead of antibiotics, for treating several diseases has been evaluated [24]. Additionally, other properties of probiotics include prevention and treatment of different cancers [25]. However, one of the innovative functions of probiotics is reducing or treatment of many inflammatory diseases [26]. E. coli Nissle1917 has a wide array of intestinal benefits for its hosts. Several antimicrobial agents, such as defensing, can inhibit adhesion and invasion of pathogenic bacteria. EcN, as a probiotic bacteria, can induce immune responses in IBD patients by defensin production [27]. Also, it has a positive effect on the expression (up-regulation) of zonula occludens (ZO) proteins (namely, ZO-1 and ZO-2) and thus repairing leaky gut phenomena [28]. Other favorable effects of EcN are related to reducing pro-inflammatory cytokines such as IL-2, TNFα, and IFNγ and increasing anti-inflammatory cytokines, which are helpful to maintain immunological homeostasis [29]. These properties might be because EcN has a specific LPS without serious immunotoxic properties and it has a strong influence on intestinal immune conditions [30]. However, some studies reported that using live microorganisms can negatively affect patients and in some cases has led to increased inflammatory conditions. Therefore, using the metabolites of microorganisms as a therapeutic agent seems to be a controversial issue. In the present study, the probiotic strain was chosen based on previous studies, which indicates that the anti-inflammatory effects of EcN can decrease inflammatory cytokine levels [29]. On the other hand, the TLR signaling pathway has a crucial effect on the pathogenesis of IBD. Also, it affects the efficiency of treatment in IBD [11]. Several functions have been recognized for TLRs, such as detection of pathogenic agents, detection of various antigens, and bridging the adaptive and innate immunity, which can regulate numerous pathways such as cytokine production, proliferation, and survival [31]. Initiating signaling pathways through TLRs function can stimulate the production of different cytokines and chemokines [32]. As there is a direct association between IBD and some TLR, understanding these pathways provides the opportunity to find out appropriate strategies for improving the treatment of IBD patients [33]. Additionally, there is a direct correlation between the alternation of TLR receptor genes and the composition of the microbiota and people who suffer from IBD have different TLR genes expression against healthy people [34]. Therefore, because of the importance of EcN in intestinal immune responses and the importance of the TLR signaling pathway in immune responses, we evaluated the vital genes in the TLR signaling pathway dysfunction of

![Fig. 2 The assessment of cell-free supernatant effect on the TLRs genes in the IBD model by Real Time PCR based on SYBR Green method.](image-url)
the immune system. The increased expressions of TLR-2, 4, 8, and 9 have been reported in CD patients while the expression of TLR5 depended on the severity of the disease [35]. In addition, the findings indicated decreased expression of TLR2, while no change was observed in the expression of TLR 4, 5, and 6. Hence, it can be speculated that EcN could improve the inflammatory condition in CD patients due to the lack of LPS (for prompting TLR-4) and flagellin (for prompting TLR-5).

Another speculation is the loss of structure and structural component after centrifuging. Thus, they could not induce some TLR-gene expressions. A previous study demonstrated that inhibition of the TLR2/6 signaling pathway has an indispensable role in the progression of IBD [36]. In this regard, our results revealed decreased TLR-2 expression along with un-changeable TLR6 expression. Hence, we assumed the inhibition of the TLR1/2 pathway. Furthermore, regarding the vital role of TLR1 signaling in mucosal protection [37], this study demonstrated that metabolites of E. coli Nissle1917 can stimulate the expression of TLR-1 significantly. Besides, based on a previous study, lack of TLR1 during gastrointestinal infection end up in the activation of chronic immunity [38], which might confirm the fact that TLR1 and its signaling pathway can inhibit inflammation in IBD patients [11]. TLR4 is another receptor that is important in IBD because it has a preliminary role in the inflammatory response against pathogenic bacteria. Therefore, it might be effective on UC diseases [39]. Nevertheless, in the present study, TLR-4 expression did not show any change. Gibson et al. demonstrated that TLR-2 had a protective effect against different dangerous agents and TLR-2 could maintain mucosal integrity against increased inflammatory responses by the TLR-4 pathway [40]. A previous study indicated the conspicuous down-regulation of TLR3 and TLR7 in epithelial cells of patients who suffer from IBD [41]. Besides, other studies showed a direct correlation between TLR3/TLR-7 genetic variation and the severity of UC disease [42, 49].

Conclusion

Finally, mechanistic exploration of the function of the component in different pathways can help design innovative therapeutic agents in several medical aspects.

Limitation

It is necessary to mention some limitations and biases of our study, including evaluating a few number of cytokines, which should be addressed in future studies.

Abbreviations

PRRs: Pattern recognition receptors; TLR: Toll-like receptors; MYD88: Myeloid differentiation primary response 88; IRAK: Interleukin receptor-associated kinase; IBD: Inflammatory bowel disease; CD: Crohn’s disease; UC: Ulcerative colitis; EcN: E. coli Nissle1917; IFN: Interferon; TRIF: TIR-domain-containing adapter-inducing interferon-β; NFKB: Nuclear kappa beta; UEV1A: Ubiquitin-conjugating enzyme E2 variant 1; MAP: Mitogen-activated protein; IκB: Inhibitor of nuclear factor-kB; TAK: Transforming-growth factor-k-activated kinase.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13104-021-05568-x.

Additional file 1: Figure S1. Important key mediator genes in Toll-Like Receptors (TLRs) signaling pathway.

Acknowledgements

We would like to thank the staff of Islamic Azad University, Tehran Medical Branch, for their cooperation.

Authors’ contributions

Conception and design: SF and AB. Contribution in laboratory work: SD and MV. Data analysis: AG and AB. Manuscript drafting: SD, SH, MR and AB. Manuscript revision: SF and AB. All authors read and approved the final manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests

The authors declare that they have no conflicting interests.

Author details

1Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran. 2Department of Biology, Faculty of Science, Nourdamesh Institute of Higher Education, Isfahan, Iran. 3Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran. 4Department of Basic and Applied Science for Engineering, Civil and Industrial Engineering Faculty, Sapienza University of Rome, Rome, Italy.

Received: 23 December 2020   Accepted: 13 April 2021
Published online: 26 April 2021

References

1. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–22.
2. Klein A, Elakim R. Non steroidal anti-inflammatory drugs and inflammatory bowel disease. Pharmaceuticals. 2010;3(4):1084–92.
3. Peloquin JM, Nguyen DD. The microbiota and inflammatory bowel disease: insights from animal models. Anaerobe. 2013;24:102–6.
4. Jonkers D, Stockbrügger R. Probiotics and inflammatory bowel disease. J R Soc Med. 2003;96(4):167–71.
5. Jia K, Tong X, Wang R, Song X. The clinical effects of probiotics for inflammatory bowel disease: a meta-analysis. Medicine. 2018;97(51):e13792.
6. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Front Immunol. 2014;5:461.

7. Gay NJ, Symmons MF, Gangloff M, Bryant CE. Assembly and localization of toll-like receptor signalling complexes. Nat Rev Immunol. 2014;14(8):546–58.

8. Sellige G, Kufar TA. PRR-signaling pathways: learning from microbial tactics. Semin Immunol. 2015;27(2):75–84.

9. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, et al. Cutting edge: a novel Toll-1-like receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. J Immunol. 2002;169(12):6668–72.

10. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84.

11. Lu Y, Li X, Liu S, Zhang Y, Zhang D. Toll-like receptors and inflammatory bowel disease. Front Immunol. 2018;9:72.

12. Souza EL, Elain SD, Paula LM, Garcia CC, Vieira AT, Teixeira MM, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis by modulating intestinal permeability, the inflammatory response and clinical signs in a faecal transplantation model. J Med Microbiol. 2016;65(3):201–10.

13. Aminnezhad A, Løkke S, Zähringer U, Ranjbar R. Evaluation of synergistic interactions between cell-free supernatant of Lactobacillus strains and Amikacin and Genetamicin against Pseudomonas aeruginosa. Jundisap J Microbiol. 2015;8(4):16592.

14. Marques JL, Funck GD, Dannenberg GDS, Cruzen C, Halal S, Dias ARG, et al. Bacteriocin-like substances of Lactobacillus curvatus P99: characterization and application in biodegradable films for control of Listeria monocytogenes in cheese. Food Microbiol. 2017;63:159–63.

15. Dosh RH, Jordan-Mahy N, Sammon C, Le Maitre CL. Long-term in vitro 3D hydrogel co-culture model of inflammatory bowel disease. Sci Rep. 2019;9(1):1812.

16. Gadjàc M, Spengler G, Sannmart C, Març MA, Handzik D, Dominguez-Alvarez E. Selenoesters and selenohydrines as novel multidrug resistance reversing agents: a confirmation study in a colon cancer MDR cell line. Bioorg Med Chem Lett. 2017;27(4):797–802.

17. Bua A, Usai D, Donadu MG, Delgado Ospina J, Paparella A, Chaves-Lopez C, et al. Antimicrobial activity of Austraeostomum nivalatum (H.B.K) against intracellular and extracellular organisms. Nat Prod Res. 2018;32(23):2867–71.

18. Javanmard A, Ashfar H, Sabet B, Davoodi SH, Rostami-Nejad M, Esmaeil Akbari M, et al. Probiotics and their role in gastrointestinal cancers preventing and treatment; an overview. GastroenterolHepatol Bed Bench. 2018;11(4):284–95.

19. Farruga M, Barón B. The role of toll-like receptors in autoimmune diseases failure through the self-recognition mechanism. Int J Inflamm. 2017;2017:8391230.

20. Asquith MJ, Boulard O, Powrie F, Maloy KJ. Pathogenic and protective tactics. Semin Immunol. 2015;27(2):75–84.

21. Dudek-Wicher R, Junka A, Paleczny J, Bartoszewicz M. Clinical trials of probiotic strains in selected disease entities. Int J Microbiol. 2020;2020:8854119.

22. Melo RS, Albuquerque Azevedo AM, Gomes Pereira AM, Rocha RR, Bastos O. MyD88-dependent and independent pathways of toll-like receptor-4 dependent pathways. Infect Immun. 2006;74(7):4075–82.

23. Sánchez-Muñoz F, Fonseca-Camarillo G, Villeda-Ramírez MA, Miranda-Pérez E, Mendivil EJ, Barreto-Zúñiga R, et al. Transcript levels of toll-like receptors 8 and 9 correlate with inflammatory activity in Ulcerative Colitis. BMC Gastroenterol. 2011;11:138.

24. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today. 2006;36(3):287–90.

25. Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, et al. Bacteriocin-like substances of Lactobacillus curvatus P99: characterization and application in biodegradable films for control of Listeria monocytogenes in cheese. Food Microbiol. 2017;63:159–63.

26. Gupta V, Datta P. Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids. Indian J Med Res. 2019;149(2):97–106.

27. Yang JY, Kim MS, Kim E, Cheon JH, Lee YS, Kim Y, et al. Enteric Viruses Triptolide in ligand-stimulated macrophages. BMC ChemBiol. 2010;10:3.

28. Guo S, Chen S, Ma J, Ma Y, Zhu J, Ma Y, et al. Escherichia coli Nissle 1917 protects intestinal barrier function by inhibiting NF-κB-mediated activation of the MLCK-P-MLC signaling pathway. MediatInflamm. 2019;2019:5796491.

29. Gutiérrez AK, Løkke S, Zähringer U, Sonnenborn U, Enders C, Gatermann S, et al. Anti-inflammatory modulation of immune response by probiotic Escherichia coli Nissle 1917 in human blood mononuclear cells. Innate Immun. 2012;18(2):204–16.

30. Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, et al. A single nucleotide exchange in the wzy gene is responsible for the semisour O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol. 2002;184(21):5912–25.

31. Idyia MK, Kuraj VG, Sejian V, Bagath M, Krishnan G, Bhatta R. Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol. 2018;37(1):20–36.

32. Nie L, Cai SY, Shao JZ, Chen J. Toll-like receptors, associated biological roles, and signaling networks in non-mammals. Front Immunol. 2018;9:1523.

33. Grabig A, Paldik D, Guzy C, Danko A, Baumgart DC, Eckenberg J, et al. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor-2 and toll-like receptor-4 dependent pathways. Infect Immun. 2006;74(7):4075–82.

34. Sugiura Y, Kamdar K, Khakpour S, Young G, Karpus WJ, DePaolo RW. TRIL-induced chemokine production is critical for mucosal immunity against Yersinia enterocolitica. Mucosal Immunol. 2013;6(6):1101–9.

35. Kamdar K, Khakpour S, Chen J, Leone V, Brulc J, Mangatou T, et al. Genetic and metabolic signals during acute enteric bacterial infection alter the microbiota and drive progression to chronic inflammatory disease. Cell Host Microbe. 2016;19(1):121–31.

36. Tojyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M. The expression patterns of Toll-like receptors in the ileal pouch mucosa of postoperative ulcerative colitis patients. Surg Today. 2006;36(3):287–90.

37. Premkumar V, Dey M, Dom R, Raskin I. MyD88-dependent and independent pathways of toll-like receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chem Biol. 2010;10:3.

38. Yang JY, Kim MS, Kim E, Cheon JH, Lee YS, Kim Y, et al. Enteric Viruses Bacteriocin-like substances of Lactobacillus curvatus P99: characterization and application in biodegradable films for control of Listeria monocytogenes in cheese. Food Microbiol. 2017;63:159–63.

39. Farruga M, Barón B. The role of toll-like receptors in autoimmune diseases failure through the self-recognition mechanism. Int J Inflamm. 2017;2017:8391230.

40. Chen Y, Zeng Z, Shen X, Wu Z, Dong Y, Cheng JC. MicroRNA-146a-5p negatively regulates pro-inflammatory cytokine secretion and cell activation in lipopolysaccharide stimulated human hepatic stellate cells through inhibition of toll-like receptor 4 signaling pathways. Int J Mol Sci. 2016;17(7):1076.

41. Jiji W, Wang P, Xie Z, Yang R, Li Y, Wu X, et al. Elevated TRAF4 expression impaired LPS-induced autophagy in mesenchymal stem cells from ankylosing spondylitis patients. Exp Mol Med. 2017;49(6):e343.

42. Reddy D, Kumavath R, Ghosh P, Barh D. Lanatoside C induces G2/M cell cycle arrest and suppresses cancer cell growth by attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR signaling pathways. Biomolecules. 2019;9(12):792.
48. Kong X, Hu S, Yuan Y, Du Y, Zhu Z, Song Z, et al. Analysis of IncRNA, miRNA and mRNA-associated ceRNA networks and identification of potential drug targets for drug-resistant non-small cell lung cancer. J Cancer. 2020;11(11):3357–68.

49. Nakamura M, Funami K, Komori A, Yokoyama T, Aiba Y, Araki A, et al. Increased expression of Toll-like receptor 3 in intrahepatic biliary epithelial cells at sites of ductular reaction in diseased livers. Hep Int. 2008;2(2):222–30.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.